Effective combination therapy of polymyxin-b direct hemoperfusion and recombinant thrombomodulin for septic shock accompanied by disseminated intravascular coagulation: A historical controlled trial

Therapeutic Apheresis and Dialysis

Volumn 17, Issue 5, 2013, Pages 472-476

  Yamato, Masafumi ^a   Minematsu, Yusuke ^a   Fujii, Junya ^a   Mori, Kohei ^a   Minato, Takumi ^a   Miyagawa, Sachie ^a   Fujimura, Ryuta ^a   Morikage, Naoko ^a   Arata, Yuka ^a   Nakano, Chisako ^a   Wada, Akira ^a   Ito, Takahito ^a  

^a OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

Disseminated intravascular coagulation; High Mobility Group Box 1; Polymyxin B direct hemoperfusion; Recombinant thrombomodulin; Septic shock

Indexed keywords

POLYMYXIN B; RECOMBINANT THROMBOMODULIN;

AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE STORM; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; FEMALE; HEMOPERFUSION; HUMAN; MALE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SURVIVAL RATE;

DISSEMINATED INTRAVASCULAR COAGULATION; HIGH MOBILITY GROUP BOX 1; POLYMYXIN-B DIRECT HEMOPERFUSION; RECOMBINANT THROMBOMODULIN; SEPTIC SHOCK;

AGED; CYTOKINES; DISSEMINATED INTRAVASCULAR COAGULATION; ENDOCANNABINOIDS; FEMALE; FOLLOW-UP STUDIES; HEMOPERFUSION; HMGB1 PROTEIN; HUMANS; MALE; MULTIPLE ORGAN FAILURE; POLYMYXIN B; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SHOCK, SEPTIC; SURVIVAL RATE; THROMBOMODULIN;

EID: 84885771028     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12112     Document Type: Article

References (19)

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.
2. Takeuchi O, Hoshino K, Kawai T etal. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 1999;11:443-451.
3. Wang H, Bloom O, Zhang M etal. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-251.
4. Wang H, Yang H, Tracey KJ etal. Extracellular role of HMGB1 in inflammation and sepsis. J Inter Med 2004;255:320-331.
5. Hatada T, Wada H, Nobori T etal. Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 2005;94:975-979.
6. Vincent JL, Laterre PF, Cohen J etal. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005;23:400-405.
7. Cruz DN, Antonelli M, Fumagalli R etal. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009;301:2445-2452.
8. Wang Y, Liu Y, Sarker KP etal. Polymyxin B binds to anandamide and inhibits its cytotoxic effect. FABS Lett 2000;470:151-155.
9. Kobayashi M. Effects of Direct Hemoperfusion with Polymyxin B Immobilized Fiber (PMX-DHP) for Patients with Septic Multiple Organ Failure. Jpn Apheresis 2010;29:266-271.
10. Nishibori M, Takahashi H, Katayama H etal. Specific removal of monocytes from peripheral blood of septic patients by polymyxin B-immobilized filter column. Acta Med Okayama 2009;63:65-69.
11. Ito T, Kawahara K, Okamoto K etal. Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol 2008;10:1825-1830.
12. Abeyama K, Stern DM, Ito Y etal. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel anti-inflammatory mechanism. J Clin Invest 2005;115:1267-1274.
13. Gando S, Iba T, Eguchi Y etal. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006;34:625-631.
14. Kobayashi M. Effects of direct hemoperfusion with polymyxin B immobilized fiber (PMX-DHP) on septic multiple organ failure. J Abdomin Emerg Med 2007;27:45-49.
15. Kobayashi M. Effects of PMX-DHP treatment for patients with septic acute lung injury/acute respiratory distress syndrome. ICU & CCU 2009;33:119-125.
16. Ogawa Y, Yamakawa K, Ogura H etal. Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. J Trauma 2012;72:1150-1157.
17. Kudo D, Shinozawa Y, Yamanouchi S etal. Treatment effect of thrombomodulin-α on septic disseminated intravascular coagulation (DIC): a historical cohort study. J Jpn Soc Intensive Care Med 2012;19:359-366.
18. Yamato M, Minematsu Y, Kuroiwa T etal. Three Septic Cases: putative Role of a Combination of Polymyxin-B Direct Hemoperfusion and Recombinant Thrombomodulin for Treating Septic Shock Accompanied by Disseminated Intravascular Coagulation. Jpn J Crit Care Endotoxemia 2012;16:148-153.
19. Mitaka C, Tsuchida N, Kawada K etal. A longer duration of polymyxin B-immobilized fiber column hemoperfusion improves pulmonary oxygenation in patients with septic shock. Shock 2009;32:478-483.